Factors Influencing the Efficacy of Anti-Pd-1 Therapy in Chinese Patients With Advanced Melanoma

Journal of Oncology - United States
doi 10.1155/2019/6454989
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Hindawi Limited

Related search

Ineffective Anti PD-1 Therapy After BRAF Inhibitor Failure in Advanced Melanoma

BMC Cancer
Cancer ResearchOncologyGenetics
2018English

Comment on ‘Efficacy and Toxicity of Treatment With the Anti-Ctla-4 Antibody Ipilimumab in Patients With Metastatic Melanoma After Prior Anti-Pd-1 Therapy’

British Journal of Cancer
Cancer ResearchOncology
2017English

Site‐specific Response Patterns, Pseudoprogression, and Acquired Resistance in Patients With Melanoma Treated With Ipilimumab Combined With Anti–PD‐1 Therapy

Cancer
Cancer ResearchOncology
2019English

Cutaneous Adverse Events (AEs) of Anti-Programmed Cell Death (PD)-1 Therapy in Patients With Metastatic Melanoma: A Single-Institution Cohort

Journal of the American Academy of Dermatology
Dermatology
2016English

Safety and Tumor Responses With Lambrolizumab (Anti–PD-1) in Melanoma

New England Journal of Medicine
Medicine
2013English

OA05.01 Efficacy/Safety of Entinostat (ENT) and Pembrolizumab (PEMBRO) in NSCLC Patients Previously Treated With Anti-Pd-(L)1 Therapy

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P104 Anti-Pd-1 Combination Therapy in Second or Later Lines in Patients With Advanced Non Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.04-21 Antibiotics Attenuate the Clinical Benefit of Anti-Pd-(L)1 Immunotherapies in Chinese Patients With Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Comprehensive Molecular and Clinical Characterization of Asian Melanoma Patients Treated With Anti-Pd-1 Antibody

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy